|Bid||0.00 x 900|
|Ask||0.00 x 1000|
|Day's range||180.21 - 182.67|
|52-week range||99.91 - 187.45|
|Beta (5Y monthly)||1.28|
|PE ratio (TTM)||59.23|
|Earnings date||27 Oct 2021 - 01 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||177.36|
Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALXN vs. TECH: Which Stock Is the Better Value Option?
AstraZeneca (NASDAQ: AZN) hopes to soon close its planned acquisition of Alexion Pharmaceuticals (NASDAQ: ALXN). In this Motley Fool Live video recorded on July 7, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not the Alexion acquisition is a good deal for AstraZeneca. Keith Speights: AstraZeneca has experienced multiple problems with the launch of its COVID-19 vaccine and we're not going to get into all of those problems but there's more news non-COVID related for AstraZeneca now.